New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Williams County Public Library will hold a retirement reception in honor of Stryker Library Assistant Linda Woodall.

Indiana star Tyrese Haliburton says the Pacers must keep their focus firmly on the Oklahoma City Thunder and block out the ...

Stryker stock ended Monday with a flatline finish, but the day itself was anything but boring. The price action played out ...

Investing.com -- Moody’s Ratings upgraded Stryker Corporation (NYSE: SYK )’s senior unsecured notes to A3 from Baa1 on Wednesday, while revising the company’s outlook to stable from positive.

Stryker stock started the week limping, gapping down at the open and slipping to a low of $373.36 before showing a mild ...